Lycia Therapeutics files for IPO, discloses Phase 1 IgE degrader data
The clinical-stage biotech, which applied to list on Nasdaq under "LYCA," reported preliminary results for LCA-0061 and detailed its LYTAC pipeline in an October 5, 2026 S-1 filing.
Lycia Therapeutics filed a registration statement with the SEC on October 5, 2026 for an initial public offering of common stock. The company said it has applied to list its common stock on the Nasdaq Global Market under the symbol "LYCA," with the offering contingent on that listing approval.1
Lycia is a clinical-stage biotechnology company focused on degrading disease-causing extracellular proteins using its proprietary LYTAC platform, with an initial focus on autoimmune, inflammatory and allergic diseases.1 Its IgE program includes two candidates: LCA-0061 and LCA-0062, both designed to degrade IgE for the treatment of allergic diseases, including food allergy.1
The company is conducting a Phase 1 clinical trial of LCA-0061 in participants with elevated IgE, including patients with food allergy.1 Early findings disclosed in the filing showed that a single 70 mg subcutaneous dose of LCA-0061 in the first cohort of healthy atopic participants produced rapid, deep and sustained reductions in total and free IgE, with no safety signals or dose-limiting toxicities, and a mean maximum IgE reduction of 96% from baseline, with most participants still above 95% reduction 28 days post-dose.1 The company said it expects additional data in healthy participants with elevated IgE and food allergy patients.1
LCA-0062 remains earlier-stage: the company is conducting IND-enabling activities for LCA-0062 and, if it receives regulatory clearance, intends to initiate a Phase 1 trial.1
Separately, Lycia is conducting a Phase 1 trial of LCA-0321 in patients with Graves' disease.1
Financially, Lycia reported a net loss of $36.5 million for 2025 and $19.2 million for the six months ended June 30, 2026, with an accumulated deficit of $136.8 million as of that date.1 It held $148.1 million in cash, cash equivalents and marketable securities as of June 30, 2026.1 Joint book-running managers for the offering are Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities, with LifeSci Capital as passive book-running manager.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.